- 期刊
A Network Meta‐analysis of Renal Outcomes in Trials of New Antidiabetic Drug in Type 2 Diabetes Mellitus
摘要
The prevalence of diabetic kidney disease (DKD) is increasing year by year. DKD is one of the most common microvascular complications of diabetes and has become the main cause of end‐stage renal failure. In recent years, the clinical application of many new hypoglycemic drugs has been increasing gradually, which can effectively reduce blood glucose while showing different degrees of renal protective effect. The renal outcomes of different novel hypoglycemic agents in the treatment of type 2 diabetes were compared and the effect of the use of these novel agents on DKD progression was discussed.
參考文獻
Cho N H, Shaw J E, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138:271-281.
Alicic R Z, Rooney M T, Tuttle K R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities[J]. Clin J Am Soc Nephrol, 2017, 12 (12): 2032-2045.
Webster A C, Nagler E V, Morton R L, et al. Chronic Kidney Disease[J]. Lancet, 2017, 389(10075): 1238-1252.
Hassanien A A, Al-Shaikh F, Vamos E P, et al. Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review[J]. JRSM Short Rep,2012,3(6):38.
Inzucchi S E, Bergenstal R M, Buse J B, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetologia,2015,58(3):429-442.